Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDG PET/CT imaging as a biomarker in lymphoma.

Literature DB >> 25573631

FDG PET/CT imaging as a biomarker in lymphoma.

Michel Meignan¹, Emmanuel Itti, Andrea Gallamini, Anas Younes.

Abstract

FDG PET/CT has changed the management of FDG-avid lymphoma and is now recommended as the imaging technique of choice for staging and restaging. The need for tailoring therapy to reduce toxicity in patients with a favourable outcome and for improving treatment in those with high-risk factors requires accurate diagnostic methods and a new prognostic algorithm to identify different risk categories. New drugs are used in relapsed/refractory patients. The role of FDG PET/CT as a biomarker in this context is summarized in this review. New trends in FDG metabolic imaging in lymphoma are addressed including metabolic tumour volume measurement at staging and integrative PET which combines PET data with clinical and molecular markers or other imaging techniques. The quantitative approach for response assessment which is under investigation and is used in large ongoing trials is compared with visual criteria. The place of FDG in the era of targeted therapy is discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25573631 DOI： 10.1007/s00259-014-2973-6

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

63 in total

1. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

Authors: Paolo G Gobbi; Emilio Bassi; Manuela Bergonzi; Francesco Merli; Chiara Coriani; Emilio Iannitto; Stefano Luminari; Giuseppe Polimeno; Massimo Federico
Journal: Hematol Oncol Date: 2012-01-23 Impact factor: 5.271

2. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.

Authors: Hélène Lanic; Sylvain Mareschal; Férial Mechken; Jean-Michel Picquenot; Marie Cornic; Catherine Maingonnat; Philippe Bertrand; Florian Clatot; Elodie Bohers; Aspasia Stamatoullas; Stéphane Leprêtre; Vinciane Rainville; Philippe Ruminy; Christian Bastard; Hervé Tilly; Stéphanie Becker; Pierre Vera; Fabrice Jardin
Journal: Leuk Lymphoma Date: 2011-08-01

3. Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells.

Authors: Michel Meignan
Journal: Eur J Nucl Med Mol Imaging Date: 2014-09 Impact factor: 9.236

4. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.

Authors: Michel Meignan; Andrea Gallamini; Emmanuel Itti; Sally Barrington; Corinne Haioun; Aaron Polliack
Journal: Leuk Lymphoma Date: 2012-04-23

5. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Authors: Caroline Bodet-Milin; Cyrille Touzeau; Christophe Leux; Mehmet Sahin; Anne Moreau; Hervé Maisonneuve; Nadine Morineau; Henry Jardel; Philippe Moreau; Céline Gallazini-Crépin; Pascal Gries; Rémy Gressin; Jean-Luc Harousseau; Mohamad Mohty; Philippe Moreau; Françoise Kraeber-Bodere; Steven Le Gouill
Journal: Eur J Nucl Med Mol Imaging Date: 2010-04-29 Impact factor: 9.236

6. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544

7. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.

Authors: Michel Meignan; Myriam Sasanelli; René Olivier Casasnovas; Stefano Luminari; Federica Fioroni; Chiara Coriani; Helene Masset; Emmanuel Itti; Paolo G Gobbi; Francesco Merli; Annibale Versari
Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-26 Impact factor: 9.236

8. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Authors: Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt
Journal: Lancet Oncol Date: 2008-04-08 Impact factor: 41.316

9. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.

Authors: Maroun Karam; Ashar Ata; Kevin Irish; Paul J Feustel; Felix M Mottaghy; Sigrid G Stroobants; Gregor E Verhoef; Surya Chundru; Vonda Douglas-Nikitin; Ching-yee Oliver Wong; Lieselot M Brepoels
Journal: Nucl Med Commun Date: 2009-10 Impact factor: 1.690

10. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.

Authors: Christine A Ciunci; Rodolfo F Perini; Anjali N Avadhani; Hyunseon C Kang; Weijing Sun; Maryann Redlinger; Kathleen Harlacker; Keith T Flaherty; Bruce J Giantonio; Mark A Rosen; Chaitanya R Divgi; Hee Kwon Song; Sarah Englander; Andrea Troxel; Mitchell Schnall; Peter J O'Dwyer
Journal: Cancer Date: 2013-09-24 Impact factor: 6.860

22 in total

Review 1. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography.

Authors: Michel Meignan; Martin Hutchings; Lawrence H Schwartz
Journal: Oncologist Date: 2015-07-14

Review 2. Current Role of Functional Imaging in the Management of Lymphoma.

Authors: Bruce D Cheson; Michel Meignan
Journal: Curr Oncol Rep Date: 2021-11-04 Impact factor: 5.075

Review 3. Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors: Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal: PET Clin Date: 2022-01

4. ¹⁸F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Authors: Kirstin A Zettlitz; Richard Tavaré; Wen-Ting K Tsai; Reiko E Yamada; Noel S Ha; Jeffrey Collins; R Michael van Dam; John M Timmerman; Anna M Wu
Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-19 Impact factor: 9.236

Review 5. Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors: A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal: Q J Nucl Med Mol Imaging Date: 2015-07-24 Impact factor: 2.346

6. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.

Authors: Marie-Hélène Delfau-Larue; Axel van der Gucht; Jehan Dupuis; Jean-Philippe Jais; Isabelle Nel; Asma Beldi-Ferchiou; Salma Hamdane; Ichrafe Benmaad; Gaelle Laboure; Benjamin Verret; Corinne Haioun; Christiane Copie-Bergman; Alina Berriolo-Riedinger; Philippine Robert; René-Olivier Casasnovas; Emmanuel Itti
Journal: Blood Adv Date: 2018-04-10

7. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

Authors: Mathieu Nessim Toledano; P Desbordes; A Banjar; I Gardin; P Vera; P Ruminy; F Jardin; H Tilly; S Becker
Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-17 Impact factor: 9.236